Regional Variation in Recommended Treatments for Ischemic Stroke and TIA: Get With the Guidelines-Stroke 2003–2010

Background and Purpose— Secondary stroke prevention treatments vary in different regions of the US. We determined the degree to which guideline-recommended stroke treatments vary by region for patients treated at hospitals participating in a voluntary national quality improvement program, Get With The Guidelines-Stroke. Methods— Receipt of 8 guideline-recommended treatments (intravenous tissue-type plasminogen activator, antihypertensives, antithrombotics, anticoagulants for atrial fibrillation, deep vein thrombosis prophylaxis, lipid-lowering medications at discharge, smoking cessation counseling, weight loss education) and defect-free care were compared in 4 US regions among eligible patients with ischemic stroke and transient ischemic attack; there was adjustment for patient demographics, medical history, and hospital characteristics. Results— Among 991 995 admissions (South, 37%; Northeast, 27.6%; Midwest, 19.3%; West, 15.9%). Receipt varied regionally for tissue-type plasminogen activator (58.2%–67.8%), lipid-lowering medications (72.5%–75.7%), antihypertensives (80.1%–83.6%), antithrombotics (95.6%–96.8%), deep vein thrombosis prophylaxis (88.0%–91.4%), weight loss education (49.3%–54.7%), and defect-free care (72.1%–76.5%). In adjusted analyses, patients in the South had lower odds of use of intravenous tissue-type plasminogen activator (OR [95% CI]; 0.82 [0.69–0.97]), antihypertensives (0.82 [0.67–0.99]), and defect-free care (0.83 [0.75–0.92]); but, they were more likely to receive lipid-lowering medications (1.28 [1.05–1.54]) compared with those in the Northeast. Patients in the Midwest had lower odds of intravenous tissue-type plasminogen activator administration (0.82 [0.68–0.99]) and defect-free care (0.81 [0.72–0.92]). Those in the West had lower odds of antihypertensives (0.81 [0.67–0.99]), but had greater odds of receiving lipid-lowering medications (1.26 [1.03–1.53]). Conclusions— Despite relatively high rates of adherence to stroke-related therapies in Get With The Guidelines-Stroke hospitals, regional variations exist, with over one quarter of patients receiving suboptimal care. Systematic improvements may lead to better patient outcomes.

[1]  E. Peterson,et al.  Secondary preventive medication persistence and adherence 1 year after stroke , 2011, Neurology.

[2]  D. Bravata,et al.  Use of Antithrombotic Medications Among Elderly Ischemic Stroke Patients , 2011, Circulation. Cardiovascular quality and outcomes.

[3]  E. Peterson,et al.  Persistence with stroke prevention medications 3 months after hospitalization. , 2010, Archives of neurology.

[4]  Kimberly S. Maier,et al.  Patient-Level and Hospital-Level Determinants of the Quality of Acute Stroke Care: A Multilevel Modeling Approach , 2010, Stroke.

[5]  T. Holford,et al.  Trends in One-Year Recurrent Ischemic Stroke among the Elderly in the USA: 1994–2002 , 2010, Cerebrovascular Diseases.

[6]  Eric E. Smith,et al.  Race/Ethnicity, Quality of Care, and Outcomes in Ischemic Stroke , 2010, Circulation.

[7]  T. Holford,et al.  Geographic Variation in One-Year Recurrent Ischemic Stroke Rates for Elderly Medicare Beneficiaries in the USA , 2010, Neuroepidemiology.

[8]  L. Goldstein,et al.  Hospital Arrival Time and Intravenous t-PA Use in US Academic Medical Centers, 2001–2004 , 2009, Stroke.

[9]  Xin Tong,et al.  Paul Coverdell National Acute Stroke Registry Surveillance - four states, 2005-2007. , 2009, Morbidity and mortality weekly report. Surveillance summaries.

[10]  R. Hornung,et al.  US Geographic Distribution of rt-PA Utilization by Hospital for Acute Ischemic Stroke , 2009, Stroke.

[11]  L. Goldstein,et al.  Stroke Patient Outcomes in US Hospitals Before the Start of the Joint Commission Primary Stroke Center Certification Program , 2009, Stroke.

[12]  Eric E. Smith,et al.  Quality of Care in Women With Ischemic Stroke in the GWTG Program , 2009, Stroke.

[13]  Li Liang,et al.  Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack , 2009, Circulation.

[14]  A. Rabinstein.  Get With the Guidelines–Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack , 2009 .

[15]  Carlos G. Grijalva,et al.  Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine - United States, 1997-2006. , 2009 .

[16]  S. Tuhrim,et al.  The association of race and sex with the underuse of stroke prevention measures. , 2008, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[17]  S. Cramer,et al.  Stroke care delivery before vs after JCAHO stroke center certification , 2006, Neurology.

[18]  Mary G. George,et al.  The Paul Coverdell National Acute Stroke Registry (PCNASR): a public health initiative. , 2006, American journal of preventive medicine.

[19]  S. Johnston,et al.  Antihypertensive Medications Prescribed at Discharge After an Acute Ischemic Cerebrovascular Event , 2005, Stroke.

[20]  California Acute Stroke Pilot Registry Investigators.  The impact of standardized stroke orders on adherence to best practices , 2005, Neurology.

[21]  Lynn A Smaha,et al.  The American Heart Association Get With The Guidelines program. , 2004, American heart journal.

[22]  M. Hammer,et al.  Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. , 2004, Archives of neurology.

[23]  S. Levine,et al.  Acute Ischemic Stroke in Hospitalized Medicare Patients: Evaluation and Treatment , 2003, Stroke.

[24]  P. Lapuerta,et al.  Regional variation in health care utilization and outcomes in ischemic stroke. , 2003, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[25]  B. B. Fleming,et al.  Quality of medical care delivered to Medicare beneficiaries: A profile at state and national levels. , 2000, JAMA.

[26]  J. Grotta,et al.  Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. , 1998, Stroke.